Biocytogen's Boston Facility Earns AAALAC Accreditation, Bolstering Preclinical Research Standards
Event summary
- Biocytogen's Boston research facility received Full Accreditation from AAALAC International on June 15, 2026.
- The accreditation recognizes excellence in laboratory animal care and use, beyond regulatory requirements.
- Biocytogen's Boston facility supports drug discovery and translational research for global pharmaceutical partners.
- The company's BioMice™ platform offers genetically engineered disease models across multiple therapeutic areas.
- Biocytogen has established over 350 agreements for therapeutic antibodies and clinical assets as of December 31, 2025.
The big picture
Biocytogen's AAALAC accreditation underscores the growing emphasis on ethical and high-standard preclinical research in the biotech sector. As the industry faces increasing scrutiny over animal welfare and scientific rigor, this accreditation positions Biocytogen as a leader in translational research, potentially attracting more high-profile partnerships and investment. The company's extensive portfolio of genetically engineered disease models and antibody discovery platforms further solidifies its role in accelerating global drug discovery efforts.
What we're watching
- Partnership Expansion
- How Biocytogen's AAALAC accreditation will influence its ability to attract and retain global pharmaceutical partners.
- Regulatory Compliance
- Whether the accreditation will set a new standard for preclinical research facilities in the biotech industry.
- Scientific Output
- The pace at which Biocytogen can translate its accredited research capabilities into accelerated drug development timelines.
Related topics